R

Ultragenyx Pharmaceutical
D

RARE

37.510
USD
-1.11
(-2.87%)
مغلق
حجم التداول
34,588
الربح لكل سهم
-5
العائد الربحي
-
P/E
-6
حجم السوق
3,469,717,236
أصول ذات صلة
B
BLUE
-0.07000
(-1.74%)
3.95000 USD
C
CLRB
-0.00130
(-0.41%)
0.31570 USD
C
CRIS
-0.12000
(-4.12%)
2.79000 USD
F
FATE
-0.06000
(-6.00%)
0.94000 USD
K
KRYS
4.390
(2.44%)
184.110 USD
M
MGTX
-0.31800
(-4.98%)
6.07000 USD
S
SRPT
-3.200
(-3.11%)
99.760 USD
V
VCEL
-0.700
(-1.41%)
48.860 USD
V
VCYT
-1.540
(-4.81%)
30.460 USD
المزيد
الأخبار المقالات

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.